Fig. 7

Kaplan–Meier plots [Overall Survival (OS), Disease Specific Survival (DSS), and Progress Free Interval (PFI)]for ACBD3 expression in pan-cancers. A For pancreatic adenocarcinoma (PAAD), the prognosis was negatively related to ACBD3 expression, including OS [hazard ratio (HR) = 1.63, 95% confidence interval (CI): 1.07–2.46, p = 0.022], DSS (HR = 1.67, 95% CI: 1.05–2.67, p = 0.032), and PFI (HR = 1.32, 95% CI: 0.90 -1.94, p = 0.155). B For adrenocortical carcinoma (ACC), the prognosis was negatively related to ACBD3 expression, including OS (HR = 2.56, 95% CI: 1.17–5.61, p = 0.018), DSS (HR = 2.60, 95% CI: 1.15–5.88, p = 0.022), and PFI (HR = 4.02, 95% CI: 2.02–8.03, p < 0.001). C For sarcoma (SARC), the prognosis was negatively related to ACBD3 expression, including OS (HR = 1.66, 95% CI: 1.10–2.48, p = 0.015), DSS (HR = 1.86, 95% CI: 1.18–2.91, p = 0.007), and PFI (HR = 1.60, 95% CI: 1.14–2.24, p = 0.006). D For glioma (GBMLGG), the prognosis was negatively related to ACBD3 expression, including OS (HR = 1.47, 95% CI: 1.15–1.87, p = 0.002), DSS (HR = 1.47, 95% CI: 1.14–1.90, p = 0.003), and PFI (HR = 1.30, 95% CI: 1.05–1.61, p = 0.014